Clay Smith, MD

Professional Titles

• Director, Blood Disorders and Cell Therapies Center

Research Interests

Publications

• Chem Biol Interact. 2012 Nov 16. pii: S0009-2797(12)00233-5. doi: 10.1016/j.cbi.2012.10.026. [Epub ahead of print] Aldehyde dehydrogenases: From eye crystallins to metabolic disease and cancer stem cells. Vasiliou V, Thompson DC, Smith C, Fujita M, Chen Y. Source Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80445, USA. Electronic address: vasilis.vasiliou@ucdenver.edu.
• Int J Hematol. 2012 Dec;96(6):743-7. doi: 10.1007/s12185-012-1192-9. Epub 2012 Nov 7. Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy. McLaughlin B, Im A, Raptis A, Agha M, Hou JZ, Redner R, Duggal S, Lin Y, Smith C, Boyiadzis M. Source Division of Hematology and Oncology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15232, USA.
• Exp Hematol. 2012 Oct;40(10):857-66.e5. doi: 10.1016/j.exphem.2012.05.014. Epub 2012 Jun 6. Varying levels of aldehyde dehydrogenase activity in adult murine marrow hematopoietic stem cells are associated with engraftment and cell cycle status. Gasparetto M, Sekulovic S, Zakaryan A, Imren S, Kent DG, Humphries RK, Vasiliou V, Smith C. Source British Columbia Cancer Agency/Terry Fox Laboratory, Vancouver, British Columbia, Canada.
• Exp Hematol. 2012 Apr;40(4):318-29.e2. doi: 10.1016/j.exphem.2011.12.006. Epub 2011 Dec 20. Aldehyde dehydrogenases are regulators of hematopoietic stem cell numbers and B-cell development. Gasparetto M, Sekulovic S, Brocker C, Tang P, Zakaryan A, Xiang P, Kuchenbauer F, Wen M, Kasaian K, Witty MF, Rosten P, Chen Y, Imren S, Duester G, Thompson DC, Humphries RK, Vasiliou V, Smith C. Source British Columbia Cancer Agency/Terry Fox Laboratory, Vancouver, British Columbia, Canada.
• Parise RA, Beumer JH, Clausen DM, Rigatti LH, Ziegler JA, Gasparetto M, Smith CA, Eiseman JL. Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice. Cancer Chemother Pharmacol. 2013 Dec;72(6):1195-204. PubMed PMID: 24061865
• Br J Haematol. 2012 Jul;158(2):174-85. doi: 10.1111/j.1365-2141.2012.09170.x. Epub 2012 May 29. Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort. Toze CL, Dalal CB, Nevill TJ, Gillan TL, Abou Mourad YR, Barnett MJ, Broady RC, Forrest DL, Hogge DE, Nantel SH, Power MM, Song KW, Sutherland HJ, Smith CA, Narayanan S, Young SS, Connors JM, Shepherd JD. Source Division of Hematology, Leukemia/BMT Program of British Columbia, Vancouver General Hospital, BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada. ctoze@bccancer.bc.ca
• Blood. 2012 Apr 12;119(15):3629-37. doi: 10.1182/blood-2011-08-373621. Epub 2012 Feb 28. An acute negative bystander effect of ?-irradiated recipients on transplanted hematopoietic stem cells. Shen H, Yu H, Liang PH, Cheng H, XuFeng R, Yuan Y, Zhang P, Smith CA, Cheng T. Source Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
• Int J Cancer. 2013 Apr 15;132(8):1741-50. doi: 10.1002/ijc.27851. Epub 2012 Oct 17. Deletion of the RNA-editing enzyme ADAR1 causes regression of established chronic myelogenous leukemia in mice. Steinman RA, Yang Q, Gasparetto M, Robinson LJ, Liu X, Lenzner DE, Hou J, Smith C, Wang Q. Source Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh, Pittsburgh, PA. steinman@pitt.edu.
• Pollyea DA, Gutman JA, Gore L, Smith CA, Jordan CT. Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. Haematologica. 2014 Aug;99(8):1277-84. PubMed PMID: 25082785
• Smith C, Gasparetto M, Humphries K, Pollyea DA, Vasiliou V, Jordan CT. Aldehyde dehydrogenases in acute myeloid leukemia. Ann N Y Acad Sci. 2014 Mar;1310:58-68. PubMed PMID: 24641679
• Smith C, Gasparetto M, Jordan C, Pollyea DA, Vasiliou V. The effects of alcohol and aldehyde dehydrogenases on disorders of hematopoiesis. Adv Exp Med Biol. 2015;815:349-59. PubMed PMID: 25427917
• December 6, 2014; Blood: 124 (21)
• Stevens B, Maxson J, Tyner J, Smith CA, Gutman JA, Robinson W, Jordan CT, Lee CK, Swisshelm K, Tobin J, Wei Q, Schowinsky J, Rinella S, Lee HG, Pollyea DA. Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series. Leuk Lymphoma. 2015 Oct 27:1-8. [Epub ahead of print] PubMed PMID: 26389776.
• Smith C, Gasparetto M, Jordan C, Pollyea DA, Vasiliou V. The effects of alcohol and aldehyde dehydrogenases on disorders of hematopoiesis. Adv Exp Med Biol. 2015;815:349-59. doi: 10.1007/978-3-319-09614-8_20. Review. PubMed PMID: 25427917.
• Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R; National Comprehensive Cancer Network. Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2015 Nov;13(11):1398-435. PubMed PMID: 26553768.
• Kariminia A, Ivison S, Ng B, Rozmus J, Sung S, Varshney A, Aljurf M, Lachance S, Walker I, Toze C, Lipton J, Lee SJ, Szer J, Doocey R, Lewis I, Smith C, Chaudhri N, Levings MK, Broady R, Devins G, Szwajcer D, Foley R, Mostafavi S, Pavletic S, Wall DA, Couban S, Panzarella T, Schultz KR. CD56(bright) natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft- versus -host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results. Haematologica. 2017 Nov;102(11):1936-1946. PubMed PMID: 28935847
• Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2015 Nov;13(11):1398-435. PubMed PMID: 26553768
• Couban S, Aljurf M, Lachance S, Walker I, Toze C, Rubinger M, Lipton JH, Lee SJ, Szer J, Doocey R, Lewis ID, Huebsch L, Howson-Jan K, Lalancette M, Almohareb F, Chaudhri N, Ivison S, Broady R, Levings M, Fairclough D, Devins G, Szwajcer D, Foley R, Smith C, Panzarella T, Kerr H, Kariminia A, Schultz KR. Erratum to "Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study" [Biol Blood Marrow Transplant 2016;22:1410-1415]. Biol Blood Marrow Transplant. 2017 Mar;23(3):534. PubMed PMID: 27789277
• Gutman JA, Ross K, Smith C, Myint H, Lee CK, Salit R, Milano F, Delaney C, Gao D, Pollyea DA. Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation. Bone Marrow Transplant. 2016 Dec;51(12):1588-1593. PubMed PMID: 27400068
• Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, Smith C, Jordan CT. Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells. J Biol Chem. 2016 Oct 14;291(42):21984-22000. PubMed PMID: 27573247
• Jones CL, Stevens BM, D'Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, Pei S, Khan N, Adane B, Ye H, Krug A, Reinhold D, Smith C, DeGregori J, Pollyea DA, Jordan CT. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. Cancer Cell. 2018 Nov 12;34(5):724-740.e4. PubMed PMID: 30423294
• Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients. Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, Riemondy KA, Gillen AE, Sheridan RM, Kim J, Costello JC, Amaya ML, Inguva A, Winters A, Ye H, Krug A, Jones CL, Adane B, Khan N, Ponder J, Schowinsky J, Abbott D, Hammes A, Myers JR, Ashton JM, Nemkov T, D'Alessandro A, Gutman JA, Ramsey HE, Savona MR, Smith CA, Jordan CT. Cancer Discov. 2020 Jan 23. pii: CD-19-0710. doi: 10.1158/2159-8290.CD-19-0710. [Epub ahead of print] PMID: 31974170 Similar articles Select item 31648312 2. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, Kaiser J, Lyle L, Boggs C, Halsema K, Schowinsky JT, Rosser J, Ewalt MD, Siegele B, Rana V, Schuster S, Abbott D, Stevens BM, Jordan CT, Smith C, Pollyea DA. Blood Adv. 2019 Oct 22;3(20):2911-2919. doi: 10.1182/bloodadvances.2019000243. PMID: 31648312 Free PMC Article Similar articles Select item 31136781 3. CD123 CAR T cells for the treatment of myelodysplastic syndrome. Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E. Exp Hematol. 2019 Jun;74:52-63.e3. doi: 10.1016/j.exphem.2019.05.002. Epub 2019 May 25. PMID: 31136781 Free Article Similar articles Select item 31009835 4. Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis. Stevens B, Winters A, Gutman JA, Fullerton A, Hemenway G, Schatz D, Miltgen N, Wei Q, Abbasi T, Vali S, Singh NK, Drusbosky L, Cogle CR, Hammes A, Abbott D, Jordan CT, Smith C, Pollyea DA. Leuk Res. 2019 Jun;81:43-49. doi: 10.1016/j.leukres.2019.04.005. Epub 2019 Apr 13.
• Kent A, Vasu S, Schatz D, Monson N, Devine S, Smith C, Gutman JA, Pollyea DA. Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse. Blood Adv. 2020 Jul 14;4(13):3102-3108. PubMed PMID: 32634235
• Sharma P, Purev E, Haverkos B, Pollyea DA, Cherry E, Kamdar M, Mark T, Forsberg P, Sherbenou D, Hammes A, Rabinovitch R, Smith CA, Gutman JA. Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant. Blood Adv. 2020 May 26;4(10):2227-2235. PubMed PMID: 32442301
• Walker ZJ, Idler BM, Davis LN, Stevens BM, VanWyngarden MJ, Ohlstrom D, Bearrows SC, Hammes A, Smith CA, Jordan CT, Mark TM, Forsberg PA, Sherbenou DW. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy. Clin Cancer Res. 2021 Feb 1;27(3):819-830. PubMed PMID: 33109736
• Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, Riemondy KA, Gillen AE, Sheridan RM, Kim J, Costello JC, Amaya ML, Inguva A, Winters A, Ye H, Krug A, Jones CL, Adane B, Khan N, Ponder J, Schowinsky J, Abbott D, Hammes A, Myers JR, Ashton JM, Nemkov T, D'Alessandro A, Gutman JA, Ramsey HE, Savona MR, Smith CA, Jordan CT. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. Cancer Discov. 2020 Apr;10(4):536-551. PubMed PMID: 31974170
• Abbott D, Cherry E, Amaya M, McMahon C, Schwartz M, Winters A, Schowinsky J, Jordan CT, Smith C, Gutman JA, Pollyea DA. The propriety of upgrading responses to venetoclax? ?azacitidine in newly diagnosed patients with acute myeloid leukemia. Leuk Lymphoma. 2020 Dec 30;:1-9. [Epub ahead of print] PubMed PMID: 33375853

Practice Locations

• University of Colorado Hospital

• University of Colorado Cancer Center

Specialty Information

• Internal Medicine, Board Certification (1989)
• Hematology, Board Certification (1994, 2016)

• Cancers - Leukemia (Adult Acute)
• Cancers - Blood and Marrow Transplant
• Cancers